Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the
“Company”), a clinical-stage precision oncology company, today
announced the publication of three abstracts regarding its SMARCA
Degrader Programs at the 36th EORTC-NCI-AACR Symposium taking place
in Barcelona, Spain October 23-25, 2024. The abstracts can be found
at Conference (eortc.org).
“We are delighted to have this opportunity to share additional
information from our SMARCA degrader programs to the scientific and
medical communities as we continue to progress both the clinical
and preclinical development of these novel first-in-class
approaches for patients with high unmet needs,” stated Kris Vaddi,
Ph.D., Chief Executive Officer of Prelude.
Continued Vaddi, “In addition to the updates we will be
providing from our Phase 1 trial of PRT3789, we are looking forward
to presenting the first preclinical data from our precision
degrader antibody conjugates program. These data demonstrate that a
highly potent dual SMARCA2/4 degrader payload can be conjugated to
an antibody to specifically target tumor cells and safely induce
tumor regressions in preclinical models. This approach has
potential to replace chemotherapy payloads on ADCs and expand the
therapeutic opportunities well beyond SMARCA4 mutated cancers.”
PRT3789 is a first-in-class, potent and highly selective SMARCA2
degrader, in Phase 1 clinical development in biomarker selected
SMARCA4 mutant patients. Enrollment remains on track, and the
Company expects to conclude monotherapy dose escalation by year end
2024 and identify the biologically active dose to advance for
future trials. In addition, enrollment of patients into back-fill
cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations
and higher dose levels is ongoing. The objective is to assess
clinical activity in a more homogeneous group of patients with high
unmet need, at the biologically active dose, to support planned
discussions with regulatory agencies.
Abstracts and Presentation Times:
First Clinical Results from a Phase 1 Trial of PRT3789,
a First-in-Class Intravenous SMARCA2 Degrader, in Patients with
Advanced Solid Tumors with a SMARCA4 MutationProffered
Paper Plenary Session #3, Room 111 + 112, Thursday, October 24 from
10:00 AM – 10:12 AM (CEST)
The abstract published today included data as of a May 28, 2024
cutoff date with updated data to be presented at the conference.
The Company previously presented initial interim data from this
study at the 2024 European Society of Medical Oncology (ESMO)
Congress 2024 on September 13, 2024. A copy of this presentation
can be accessed at Guo_PRT3789-01_ESMO_presentaion_Sep2024.pdf
(preludetx.com).
Discovery of First-in-Class Precision Antibody Drug
Conjugates with a Potent SMARCA 2/4 Dual Degrader Payload that
Safely Achieve Maximal and Tumor Specific Degradation and Efficacy
in Mouse ModelsPoster Session – Antibody Drug Conjugates,
Abstract #167 Exhibition Hall Location PB155, Thursday, October 24,
9:00 AM – 5:30 PM (CEST)
The Selective SMARCA2 Degrader, PRT3789, Counteracts the
Protective Cellular Stress Response to Chemotherapy and Enhances
the Efficacy of Standard of Care Chemotherapeutic Agents in SMARCA4
Mutant NSCLC ModelsPoster Session – Combination Therapies,
Abstract #220, Exhibition Hall Location PB208, Thursday, October
24, 9:00 AM – 5:30 AM (CEST)
About Prelude
Therapeutics
Prelude Therapeutics is a leading precision oncology company
developing innovative medicines in areas of high unmet need for
cancer patients. Our pipeline is comprised of several novel drug
candidates including first-in-class, highly selective IV and oral
SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor.
We are also leveraging our expertise in targeted protein
degradation to discover, develop and commercialize next generation
degrader antibody conjugates (Precision ADCs) with partners. We are
on a mission to extend the promise of precision medicine to every
cancer patient in need. For more information, visit
preludetx.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, anticipated discovery, preclinical and clinical
development activities for Prelude’s product candidates, the
potential safety, efficacy, benefits and addressable market for
Prelude’s product candidates, and clinical trial results for
Prelude’s product candidates. All statements other than statements
of historical fact are statements that could be deemed
forward-looking statements. The words “believes,” “anticipates,”
“estimates,” “plans,” “expects,” “intends,” “may,” “could,”
“should,” “potential,” “likely,” “projects,” “continue,” “will,”
“schedule,” and “would” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are predictions based on the Company’s
current expectations and projections about future events and
various assumptions. Although Prelude believes that the
expectations reflected in such forward-looking statements are
reasonable, Prelude cannot guarantee future events, results,
actions, levels of activity, performance or achievements, and the
timing and results of biotechnology development and potential
regulatory approval is inherently uncertain. Forward-looking
statements are subject to risks and uncertainties that may cause
Prelude's actual activities or results to differ significantly from
those expressed in any forward-looking statement, including risks
and uncertainties related to Prelude's ability to advance its
product candidates, the receipt and timing of potential regulatory
designations, approvals and commercialization of product
candidates, clinical trial sites and our ability to enroll eligible
patients, supply chain and manufacturing facilities, Prelude’s
ability to maintain and recognize the benefits of certain
designations received by product candidates, the timing and results
of preclinical and clinical trials, Prelude's ability to fund
development activities and achieve development goals, Prelude's
ability to protect intellectual property, and other risks and
uncertainties described under the heading "Risk Factors" in
Prelude’s Annual Report on Form 10-K for the year ended December
31, 2023, its Quarterly Reports on Form 10-Q and other documents
that Prelude files from time to time with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date of this press release, and Prelude undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof, except as
may be required by law.
Investor Contact: Robert A. Doody
Jr.Senior Vice President, Investor
Relations 484.639.7235rdoody@preludetx.com
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Dec 2023 to Dec 2024